One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment
Authors:
Open Access
- 16 July 2022
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1-12
Abstract
Background: The novel coronavirus is still mutating, and the pandemic continues. Meanwhile, many COVID-19 survivors have residual postinfection clinical manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been shown to be effective in the early stages of COVID-19. Objectives: The aim of this study was to investigate long-term safety and efficacy of treatment in patients with severe COVID-19 patients who had received hUC-MSCs therapy. Methods: Twenty-five discharged patients who had severe COVID-19 (including the standard treatment group and the standard treatment plus hUC-MSCs group) were enrolled in a 1-year follow-up. The assessment considered adverse effects (including effects on liver and kidney function, coagulation, ECG, tumor marker, and so on), pulmonary function, St George’s Respiratory Questionnaire (SGRQ), postinfection sequelae and serum concentration of Krebs von den Lungen-6 (KL-6), malondialdehyde (MDA), H2S, carnitine, and N-6 long-chain polyunsaturated fatty acids (N-6 LC-PUFAs). Measurements and main results: Pulmonary ventilation function had significantly improved at the 1-year follow-up in both the hUC-MSCs group and the control group compared with the 3-month follow-up (P < 0.01). Fatigue (60% [15/25]) remained the most common symptom at the 1-year follow-up. The rate of fatigue relief was significantly reduced in the hUC-MSCs group (25% [2/8]) compared to the control group (76.5% [13/17]) (P = 0.028). The level of KL-6 was significantly lower in the hUC-MSCs group (2585.5 ± 186.5 U/ml) than in the control group (3120.7 ± 158.3 U/ml) (P < 0.001). Compared with the control group, the hUC-MSCs group had a lower level of MDA (9.27 ± 0.54 vs. 9.91 ± 0.72 nmol/ml, P = 0.036). No obvious adverse effects were observed in the hUC-MSCs treatment group at 1 year after discharge. Conclusions: Intravenous transplantation of hUC-MSCs was a safe approach in the long term in the treatment of patients with severe COVID-19. In addition, hUC-MSCs had a positive effect on postinfection sequelae in COVID-19 survivors. Trial registration: Chinese Clinical Trial Registration; ChiCTR2000031494; Registered 02 April 2020—Retrospectively registered, http://www.medresman.orgKeywords
Funding Information
- Natural Science Foundation of China (81870009, 82070017)
This publication has 42 references indexed in Scilit:
- H2S signalling through protein sulfhydration and beyondNature Reviews Molecular Cell Biology, 2012
- Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung diseaseRespiratory Research, 2011
- The long‐term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health statusRespirology, 2010
- Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue SyndromeScience, 2009
- One-Year Outcomes and Health Care Utilization in Survivors of Severe Acute Respiratory SyndromeArchives of internal medicine (1960), 2007
- Long-chain polyunsaturated fatty acids and the pathophysiology of myalgic encephalomyelitis (chronic fatigue syndrome)Journal of Clinical Pathology, 2006
- The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of SurvivorsChest, 2005
- Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivorsThorax, 2005
- Standardization of Spirometry, 1994 Update. American Thoracic SocietyAmerican Journal of Respiratory and Critical Care Medicine, 1995
- The St George's Respiratory QuestionnaireRespiratory Medicine, 1991